Meet UNH Manchester’s newest biotechnology faculty

Monday, November 23, 2020

Manchester has become the region’s biotechnology hub since the creation of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program, which is building an industry to regenerate human tissue and organs. As a partner in the economic development initiatives for ARMI|BioFabUSA, the University of New Hampshire at Manchester has continued to expand its offerings in the burgeoning biotech field. With the growth in its undergraduate biotechnology program and the addition of a new master’s in industrial and biomedical sciences, UNH Manchester has welcomed exceptional new talent to its biotech faculty.

These are the new scholars and teachers bringing their research and industry expertise to UNH Manchester. We can’t wait to see what they accomplish here.

Won Hyuk Suh, Ph.D.

Assistant Professor of Biotechnology

Won Suh

Won Hyuk Suh joins UNH Manchester from Temple University, where he was an assistant professor in the bioengineering department. Suh brings extensive research and scholarship in synthetic biomaterials and human stem cell engineering, including cancer treatment-related work. His research in developing a new cell penetrating peptide system has led to a patent and multiple publications. As a principal investigator on sponsored research grants, Suh developed enabling technologies that will allow stem cells and cancer cells to more efficiently undergo neuronal differentiation processes. His work also includes leading three synthetic research projects to aid in the treatment of neurological injuries, disorders and diseases, including Alzheimer’s and Parkinson’s. Suh has published more than 15 articles over the past decade.

Suh earned his Ph.D. in Chemistry at the University of Illinois at Urbana-Champaign and a B.S. and M.S. in Chemistry from Seoul National University.

Jay Hoying, Ph.D., FAHA

Affiliate Professor of Biotechnology

Jay Hoying

Jay Hoying is partner and chief scientist at Advanced Solutions Life Sciences (ASLS), a company pioneering solutions in vascularized tissue fabrication and biomanufacturing. Prior to joining ASLS, Hoying was the chief of the division of cardiovascular therapeutics at the Cardiovascular Innovation Institute and professor in the department of physiology at the University of Louisville. He has over 25 years of experience in basic and applied biological sciences research with a focus in tissue biology, tissue vascularization and cell therapeutics. Hoying is a Fellow of the American Heart Association and serves on the editorial staff of two national scientific journals and reviews for several other national and international journals. He reviews individual and program grant proposals for the National Institutes of Health, Veterans Affairs, American Heart Association and international funding agencies. In addition to his numerous published works, Hoying holds patents related to vascularizing tissues and related cell-based therapies, technologies that have been translated to companies. He was one of the first to publish in the area of vascularized tissue model fabrication.

Hoying received his Ph.D. in Cardiovascular Physiology, with an emphasis on microcirculation, from the University of Arizona and his bachelor’s and master’s degrees in biology and molecular biology from Case Western Reserve University.

Richard McFarland, Ph.D., MD

Affiliate Professor of Biotechnology

Richard McFarland

Richard McFarland is an immunopathologist and the Chief Regulatory Officer at the Advanced Regenerative Manufacturing Institute (ARMI), which is seeking to make practical the scalable manufacturing of engineered tissues and tissue-related technologies to benefit existing industries and grow new ones. In this current role, McFarland oversees regulatory affairs for ARMI and its BioFabUSA and NextFab programs. He is also one of the Principal Consultants at BioFabConsulting, working with members on regulatory issues related to product classification, regulatory strategy and manufacturing, as well as preclinical and clinical studies. McFarland also serves as president of the Standards Coordinating Body for Regenerative Medicine, a Maryland-based independent non-profit whose mission is to coordinate the accelerated advancement and improved awareness of the standards and best practices that address the rapidly evolving needs of the global regenerative medicine advanced therapy community.

McFarland received his undergraduate, graduate and medical school training at the University of North Carolina-Chapel Hill. He received his post-graduate medical specialty training in anatomic/clinical pathology and subspecialty training in immunopathology at University of Texas Southwestern Medical Center in Dallas.

Alexander Titus, Ph.D.

Affiliate Assistant Professor of Biotechnology

Alexander Titus

Alexander Titus is the Chief Strategy Officer (CSO) at the Advanced Regenerative Manufacturing Institute (ARMI) where he is part of the leadership team working to advance the U.S. regenerative manufacturing industry as well as develop technologies for disaster preparedness. A trained data scientist with expertise at the junction of AI and biology, his career is focused on the intersection of technology and public benefit, with experience spanning the private and public sectors as well as non-profits and academia. Prior to his current role, Titus was the inaugural assistant director for biotechnology within the Office of the CTO at the Department of Defense, where he led the team developing the biotechnology modernization roadmap for the DoD.

Alexander holds a Ph.D. in Quantitative Biomedical Sciences from the Guarini School of Graduate and Advanced Studies at Dartmouth, as well as a B.S. in Biochemistry and B.A. in Biology from the University of Puget Sound.


UNH offers a B.S. in Biotechnology and an M.S. in Biotechnology: Industrial and Biomedical Sciences at its Manchester campus, in the heart of the region's biotech industry.

Kassidy Taylor | Marketing & Communications, UNH Manchester |